Enlivex Therapeutics Ltd (ENLV)

[Couch]

Interesting days ahead for ORPN: Certainly a bounce play could easily be on the horizon based upon these 3 pieces of info.

1) http://ir.bioblastpharma.com/phoenix.zhtml?c=253658&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTExNTE2NjkyJkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3


Bioblast Pharma Ltd.
37 Dereh Menachem Begin St., 15th Floor
Tel-Aviv, Israel 6522042


April 6, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Re: Request to Withdraw Registration Statement on Form F-1 (File No. 333-216238)

Ladies and Gentlemen:

Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), Bioblast Pharma Ltd. (the “Registrant”) hereby requests the immediate withdrawal of the above-referenced registration statement, together with all exhibits and amendments thereto (the “Registration Statement”). The Registration Statement was initially filed with the Securities and Exchange Commission (the “Commission”) on February 24, 2017.

The Registrant is requesting to withdraw the Registration Statement because it has elected not to pursue the sale of securities pursuant to the Registration Statement at this time. The Registration Statement was not declared effective by the Commission and the Registrant confirms that no securities were sold in connection with the offering contemplated by the Registration Statement. Pursuant to Rule 477(c) under the Securities Act, the Registrant respectfully advises the Commission that the Registrant may undertake a subsequent private offering in reliance on Rule 155(c) under the Securities Act.

The Registrant further requests that, in accordance with Rule 457(p) under the Securities Act and subject to compliance with the requirements thereof, all fees paid to the Commission in connection with the filing of the Registration Statement be credited for potential future use.

Should you have any questions regarding this matter, please contact counsel to the Registrant, Shy Baranov, Esq., of Zysman, Aharoni, Gayer and Sullivan & Worcester LLP at [phone].

Very truly yours,

/s/ Fredric Price
Fredric Price
Executive Chairman of the Board of
Directors and Chief Executive Officer

2 Bioblast Pharma Announces Plans in Response to Nasdaq Notifications Regarding Stockholders’ Equity and Minimum Bid Requirements

http://finance.yahoo.com/news/bioblast-pharma-announces-plans-response-204830984.html;_ylt=AwrBT9VigPtY7ZYABJ5XNyoA;_ylu=X3oDMTByMjB0aG5zBGNvbG8DYmYxBHBvcwMxBHZ0aWQDBHNlYwNzYw--

Bioblast has a 180 day period, until October 9, 2017, to regain compliance with the $1.00 minimum bid price requirement. If at any time during this 180 day period, the closing bid price of the company’s ordinary shares is at least $1.00 for a minimum of ten consecutive business days, the company will regain compliance and the matter will be closed.

3) RSI in the oversold territory and looks to have bottomed out given #1 above.